Table 5.

Medication used in the CAA population before and after CAA diagnosis

	Before index date	After index date
	1 year	3 month	6 month	1 year
N = 811	N (%)	N (%)	N (%)	N (%)
Antithrombotic agent	555 (68.4)	680 (83.8)	700 (86.3)	722 (89.0)
Aspirin	477 (58.8)	568 (70.0)	587 (72.4)	615 (75.8)
Clopidogrel	163 (20.1)	329 (40.6)	338 (41.7)	351 (43.3)
Dipyridamole	34 (4.2)	12 (1.5)	22 (2.7)	31 (3.8)
Cilostazol	13 (1.6)	18 (2.2)	20 (2.5)	29 (3.6)
Ticlopidine	12 (1.5)	10 (1.2)	16 (2.0)	20 (2.5)
Warfarin	33 (4.1)	76 (9.4)	97 (12.0)	109 (13.4)
Antihypertensive agent	599 (73.9)	613 (75.6)	675 (83.2)	703 (86.7)
ACEI	161 (19.9)	144 (17.8)	163 (20.1)	181 (22.3)
ARBs	234 (28.9)	229 (28.2)	261 (32.2)	300 (37.0)
CCBs	348 (42.9)	283 (34.9)	324 (40.0)	371 (45.7)
β-blockers	289 (35.6)	197 (24.3)	314 (38.7)	392 (48.3)
Diuretics	171 (21.1)	181 (22.3)	210 (25.9)	237 (29.2)
α-blockers	116 (14.3)	76 (9.4)	105 (12.9)	129 (15.9)
Antidyslipidemic agents	291 (35.9)	321 (39.6)	370 (45.6)	410 (50.6)
Statins	257 (31.7)	300 (37.0)	349 (43.0)	386 (47.6)
Fibrates	53 (6.5)	24 (3.0)	31 (3.8)	50 (6.2)
Others	11 (1.4)	13 (1.6)	14 (1.7)	18 (2.2)
Antidiabetic agents	177 (21.8)	144 (17.8)	170 (21.0)	187 (23.1)
Metformin	114 (14.1)	79 (9.7)	96 (11.8)	117 (14.4)
Sulfonylureas	132 (16.3)	98 (12.1)	107 (13.2)	117 (14.4)
Thiazolidinedione (TZD)	43 (5.3)	23 (2.8)	31 (3.8)	33 (4.1)
DDP-4 inhibitors	10 (1.2)	10 (1.2)	16 (2.0)	23 (2.8)
Others	45 (5.5)	28 (3.5)	38 (4.7)	49 (6.0)
Nitrates	265 (32.7)	290 (35.8)	350 (43.2)	388 (47.8)
Nitroglycerin	43 (5.3)	11 (1.4)	27 (3.3)	74 (9.1)
Isosorbide dinitrate	57 (7.0)	58 (7.2)	75 (9.2)	86 (10.6)
Isosorbide mononitrate	184 (22.7)	216 (26.6)	246 (30.3)	267 (32.9)
Nicorandil	41 (5.1)	24 (3.0)	44 (5.4)	69 (8.5)

ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, TZD thiazolidinedione, DDP-4 inhibitor dipeptidyl peptidase-4 inhibitor